{"url_path":"/sec/chrs/8-k/2026-06-15/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1512762/0001104659-26-074090-index.html","accession_number":"0001104659-26-074090","cik":"0001512762","ticker":"CHRS","issuer_name":"Coherus Oncology, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1512762/0001104659-26-074090-index.html","primary_entity_key":"0001512762","primary_entity_name":"Coherus Oncology, Inc."},"word_count":124,"has_tables":true,"body_markdown":"**Item 9.01 Financial Statements and Exhibits.**\n\n \n\n(d) Exhibits\n\n \n\n**Exhibit No.**\n\n \n\n**Description**\n\n16.1\n\n  ​\n\n[Letter from Ernst & Young LLP to the Securities and Exchange Commission dated June 15, 2026](chrs-20260612xex16d1.htm)\n\n​\n\n​\n\n​\n\n104\n\n  ​\n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n​\n\n​\n\n​\n\n​\n\n**SIGNATURES**\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n​\n\n​\n\n​\n\n​\n\n​\n\nDate: June 15, 2026\n\n  ​ ​ ​\n\nCOHERUS ONCOLOGY, INC.\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\nBy:\n\n/s/ Dennis M. Lanfear\n\n​\n\n​\n\nName:\n\nDennis M. Lanfear\n\n​\n\n​\n\nTitle:\n\nChief Executive Officer\n\n​\n\n​\n\n​\n\n​"}